Gain Therapeutics Inc(GANX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:47 PM ET (Korea 10/31 06:47)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.51 | Insider Own | 2.93% | Shs Outstand | 43.3M | Perf Week | -10.32% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | -31.04% | Insider Trans | - | Shs Float | 42.4M | Perf Month | -34.3% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.12 | Inst Own | 20.27% | Short Float | 7.53% | Perf Quarter | -35.43% |
| Income | -0.02B | P/S | - | EPS this Y | 18.55% | Inst Trans | 1.08% | Short Ratio | 6.31 | Perf Half Y | -39.89% |
| Sales | 0.00B | P/B | 4.34 | EPS next 5Y | -3.43% | ROA | -159.22% | Short Interest | 3.19M | Perf YTD | -64.91% |
| Book/sh | 0.26 | P/C | 3.77 | EPS past 3/5Y | 25.52% -15.21% | ROE | -268.3% | 52W High | -73.96% ($4.34) | Perf Year | -35.8% |
| Cash/sh | 0.3 | P/FCF | - | Sales past 3/5Y | - | ROIC | -172.31% | 52W Low | -0.88% ($1.14) | Perf 3Y | -61.3% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 23.02% | Gross Margin | - | Volatility(W/M) | 7.27% 7.51% | Perf 5Y | -83.76% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.36 | EPS Q/Q | 43.08% | Profit Margin | - | RSI (14) | 27.33 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.36 | Sales Q/Q | - | SMA20 | -16.88% ($1.36) | Beta | 0.24 | Target Price | $7.2 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/8/11 | SMA50 | -30.32% ($1.62) | Rel Volume | 0.72 | Prev Close | $1.19 |
| Employees | 21 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 20.29% - | SMA200 | -39.24% ($1.86) | Avg Volume(3M) | 0.51M | Price | $1.13 |
| IPO | 2021/3/18 | Option/Short | Yes/Yes | Trades | 711 | Volume | 364,662 | Change | -5.04% |
🧠 The company is a clinical-stage biotech developing innovative 'allosteric' small-molecule therapeutics that leverage artificial intelligence (AI) technology to treat neurodegenerative and rare diseases. Through its proprietary 'Magellan™' AI platform, the company is working to correct structural defects in proteins and restore neural function, offering a next-generation therapeutic alternative for Parkinson's disease.
Over the past 1 year, on the lower side
74% below its 1-year high.
Traded less than usual. That is 72% of its average volume.
GANX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +18.6% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -83.8%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 20.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IBRN iShares Neuroscience and Healthcare ETF <0.01% 
IWC iShares Micro-Cap ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #415 of 597 in the industry
Based on market cap of $49M.
CNTB#413 Connect Biopharma Holdings Ltd $51M PER - 
HYPD#414 Hyperion DeFi Inc $50M PER - GANX#415 Gain Therapeutics Inc $49M PER - 
SER#416 Serina Therapeutics Inc $49M PER - 
ANVS#417 Annovis Bio Inc $48M PER - 
FAQ
What kind of company is GANX?
GANX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GANX?
The market cap of GANX is approximately $49M, ranking 4,848 within its sector.
What is the 52-week high and low for GANX?
GANX has recorded a 52-week high of $4.34 and a low of $1.14.
